Currently viewing the tag: "Belinostat"

TopoTarget at a Glance

By On 25. June 2012 · Leave a Comment · In Spectrum, Topotarget

This is TopoTarget at a glance, hopefully this will provide you with an overview of one of the most exiting Biotech companies in Denmark.

Apart from telling you a bit about the investment-opportunity, I (investor89) will also make a laymans explanation of some the abbreviations you will encounter when studying TopoTarget

TopoTarget themselves describe the […]

Continue Reading →

TopoTarget ‘s Belinostat effective in pancreatic cancer

By On 13. June 2012 · Leave a Comment · In Topotarget

Last week saw the publication of a paper on TopoTarget ‘s Berlinostat in Pancreatic Cancer. The paper was accepted  after clarification on some of the points mentioned by the reviewer –

The combination of belinostat and gemcitabine has some additive effect in vitro, yet not synergic nor significant neither confirmed by in vivo experiments.

In […]

Continue Reading →

Spectrum a future Winner

By On 9. June 2012 · Leave a Comment · In Spectrum

Being a  Danish investor I first learned about Spectrum Pharmaceuticals back in 2010, when Spectrum and Danish TopoTarget entered into an agreement on HDACi inhibitor Belinostat.

After having read extensively about the possibilities of Spectrum I decided to make a investment  in 2010, at the time the stock was trading in the 4-5 dollar range. Today […]

Continue Reading →
Set your Twitter account name in your settings to use the TwitterBar Section.